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DOI 10.1016/j.chembiol.2009.12.006Which comes first – the chicken or the
vaccine? If you know your vaccine tech-
nology, it’s an easy answer. But if you
don’t, you might wonder what the two
have in common. It is true that in the
post-molecular era, most of our seasonal
and pandemic influenza vaccines are
made using technology that dates back
to the mid 1900s. Though these vaccines
have had a high measure of success
in influenza prevention over the past
30 years or so, the opportunity—some
would say need—to create more effec-
tive, safer vaccines more quickly against
flu and similar viruses, like the current
H1N1, is technologically within reach.
‘‘For influenza and similar viruses, the
vaccines that will replace the current older
technology will be produced through.most of our seasonal and pandemic influenza vaccines are
made using technology that dates back to the mid 1900s.recombinant technology, using genetic
material to generate vaccines from cell
culture or a high production throughput
system,’’ says Ted Ross, Ph.D., Center
for Vaccine Research (CVR) at the Univer-
sity of Pittsburgh. ‘‘One of the things we
need to do is to get vaccines made more
quickly especially against pandemic out-
breaks, such as the current H1N1 experi-
ence,’’ he says.
The manufacturers licensed to manu-
facture the H1N1 vaccines fell short of
delivering the original number of 195
milliondoses theU.S. governmentordered
this summer. At the time this articlewent to
press, the Centers for Disease Control
(CDC) confirmed that about 64 million
doses have been shipped thus far. This
shortfall created the triaged system now
in place in which select groups have been
receiving the vaccines ahead of the
general public.
Chickens and Their Eggs
‘‘The H1N1 vaccine supply we make for
the United States is grown entirely inchicken eggs,’’ says Philip R. Dormitzer,
M.D., Ph.D., senior project leader, Viral
Vaccine Research at Novartis. Novartis
is one of the large companies involved
in seasonal flu and H1N1 vaccine pro-
duction. ‘‘You need an awful lot of
chickens producing literally millions of
eggs,’’ he explains. ‘‘That creates an ele-
ment of vulnerability in the vaccine supply
where you need chickens to make more
chickens to get enough eggs.’’ Each egg
must be inoculated and harvested
individually, making the process labor
intensive. And as Dormitzer puts it subtly,
‘‘Chickens and their eggs are far from
sterile, and it introduces a potential for
a bioburden which can be eliminated
with a cell-culture based or other more
advanced vaccine.’’Not only are chicken eggs needed to
function as tiny incubators, but Dormitzer
explains that flu viruses generally do not
grow terribly well in eggs. ‘‘Flu viruses
are adapted to grow in human respiratory
cells,’’ says Dormitzer. ‘‘For them to grow
in eggs, they have to be adapted to those
eggs, because eggs bear different recep-
tors on their surface than those that flu
virus use to get into humans.’’ The conse-
quences include the need to choose
a strain for production that grows in
eggs thereby placing a restriction on the
range of strains that can be used in
a vaccine. Second, to grow in eggs, flu
viruses have to undergo an adaptive
mutation to bind the egg receptors.
Explains Dormitzer, ‘‘It turns out that the
receptor binding site is in a key antigenic
region, so those viruses will always have
a slight difference from the viruses that
actually circulate in people because they
have acquired a mutation right where
many neutralizing antibodies bind.’’
Clearly, there is room for improvement.
Molecular biology now makes it possibleChemistry & Biology 16, December 24, 2009 ªto produce a safe immunogen that will
not replicate and is noninfectious but
contains all the proteins or epitopes
needed to stimulate the body’s immune
system. There are a variety of different
mechanisms to pursue this goal. Says
Ross, ‘‘It is like we’ve decided we like
ice cream but haven’t figured out which
flavor.’’
Cell Culture Vaccines
Much of the core science that will deliver
the next level of efficiency has been avail-
able since the mid 1980s. ‘‘The innovation
is really how you adapt it to an industrial
setting to really make effective vaccine,’’
says Ross. ‘‘With cell-based production
methods, such as in mammalian cell cul-
ture, bacteria, insect cell culture, or a yeast
system, you can scale them up into very
large bioreactors to safely make a lot of
product.’’
Novartis already markets a cell culture-
based H1N1 vaccine, Celtura, and has
licensed a seasonal flu vaccine, Optaflu,
in Europe. And on November 24, 2009, it
inaugurated the U.S. Flu Cell Culture
Facility in North Carolina with the mission
of being able to produce 150million doses
of flu vaccine within 6 months of the
declaration of a pandemic. When opera-
tional in 2011, the facility, which is a part-
nership between Novartis and the Depart-
ment of Health and Human Services, will
use large tanks of Madin-Darby canine
kidney (MDCK) cells as a substrate in
which to grow flu virus.
Cell culture technologies also offer the
possibility of producing vaccines without
the need for live whole virus. Novavax is
developing both seasonal flu and H1N1
vaccines using cell culture of virus-like
particles. ‘‘Virus-like particles (VPLs) look
like a virus, have all the right structures,
but contains none of the genetic informa-
tion, so they can’t replicate,’’ says Ross,
who has been involved in conducting
a trial of a VPL vaccine from Novavax.
The first VPL vaccines licensed are those
for hepatitis B virus (HBV) and the human
papillomavirus (HPV) vaccine, Gardasil.2009 Elsevier Ltd All rights reserved 1209
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clinical trials now and I would expect a few
to be licensed over the next 10 years—
particularly for influenza, rotavirus, and
respiratory synctial virus,’’ says Ross.
‘‘Another advantage with VPL vaccines
is that they can be made very quickly
compared with current technology, on
the order of 3–4 months.’’
Bacterial Fermentation
There is also work to try and decrease
production times by not growing virus
but simply producing antigens using other
expression systems.
VaxInnate, of Cranbury, New Jersey,
uses recombinant proteins in E. coli
fermentation to produce its novel influ-
enza and H1N1 vaccines. ‘‘We pick out
the sequence for part of the viral hemag-
glutinin (HA) we need, convert that
sequence into a physical DNA sequence,
and put that into an expression plasmid
in E. coli,’’ explains Alan Shaw, Ph.D.,
VaxInnate’s president and CEO. HA is
a protein located on the virus envelope
that is recognized and bound by respira-
tory cells. ‘‘We’ve demonstrated good
immunogenicity and safety with the H1N1
human strain and have made a vaccine
that will begin clinical testing in the begin-
ning of next year,’’ he says.
Shaw adds that one 1,000 liter fermen-
tation batch yields about 200 million puri-
fied vaccine doses. And it takes about
10 days to do that start-to-finish. ‘‘Had
we been licensed last July, given the
time it takes us to build the construct and
make materials, we could have been
supplying H1N1 vaccine in July of this
summer so therewould havebeenenough
for everyone,’’ he says. ‘‘This technology
allows us to take an emergency and turn
it into a routine operation.’’
Other companies using a similar
approach include Novavax and Protein
Sciences. Both companies use insect
cells instead of E. coli bacteria for their
production platforms.
Direct DNA Injection
‘‘Themost distant approach is DNA vacci-
nation,’’ says CVR’s Ronald Montelaro,1210 Chemistry & Biology 16, December 24,Ph.D. ‘‘You immunize people with DNA
and then that DNA incorporates into cells
in the skin or elsewhere and produces
those viral proteins in the body and the
immune system reacts to it. The beauty
about DNA is that you can produce a lot
of it and it is extremely stable, eliminating
the need for a cold chain.’’
Vical of San Diego, California, is in
pursuit of an influenza vaccine using
direct DNA injection. ‘‘We use E. coli to
make gene segments that are then
injected into human vaccine volunteers,’’
says Larry Smith, Ph.D., vice president,
Vaccine Research. ‘‘In our case, we take
the influenza H1 hemagglutinin gene and
clone it into our plasmid DNA backbone,
introduce it to E. coli, and grow it up in
mass quantities.’’ The vaccine is then
injected into muscle tissue. The company
tested its vaccine strategy real-time in the
wake of the Mexico City H1N1 outbreaks
in April 2009. ‘‘We took a gene sequence
from the CDC’s GenBank and had the
gene synthesized without ever touching
an H1 virus or having to worry about
biocontainment.’’ Vical claims its manu-
facturing process would require about
10 weeks to create a vaccine from the
time it receives the genetic sequence to
the initial lot release.
In October 2009, the U.S. Navy com-
mitted funding to conduct clinical, regula-
tory, and manufacturing preparations for
a phase I clinical study of Vical’s H1N1
vaccine.
Mission Impossible? Universal Flu
Vaccine
‘‘If we can make one vaccine that doesn’t
need to change yearly to account for
strain variations, that would be the Holy
Grail,’’ says Smith. But the scientific jury
is still out on whether universal vaccine
against influenza is feasible. Some say
the research needed to fully categorize
the millions of circulating influenza
strains would require an investment on
the order of the Human Genome Project.
Because influenza virus mutates and
changes so often, some suggest target-
ing a region of the virus that is highly
conserved among strains, such as the2009 ª2009 Elsevier Ltd All rights reservedM2e ion channel protein or the HA protein.
But researchers are finding that highly
conserved epitopes on HA are not the
most immunogenic. ‘‘These regions prob-
ably don’t change because they don’t
have to,’’ says Dormitzer. ‘‘It does appear
that most of the protective immune
response is directed against the variable
epitopes.’’
VaxInnate had been working on a
universal flu vaccine until this summer,
when it was revealed that the M2e
sequence of the H1N1 virus was very
different than the sequence used in the
company’s phase 1 universal flu vaccine
study.
Vical has also pursued a universal flu
vaccine incorporating the influenza nucle-
oprotein (NP) and M2e ion channel pro-
tein. ‘‘These are well-conserved proteins
among different influenza A subtypes,’’
saysSmith. ‘‘There are 16 known influenza
A hemagglutinin (HA) subtypes. Today,
seasonal flu vaccines are made using
strains from two of those 16 HA subtypes,
as well as an influenza B strain.’’
Inovio Biomedical of SanDiego, Califor-
nia, is also using direct DNA constructs,
including one for HA, to make a universal
flu vaccine. Its product is in preclinical
testing.
‘‘The other way to make a universal
vaccine is to find the common regions
on the proteins of the virus that change
quite a bit and see if you can bridge
many different strains,’’ explains Ross.
‘‘I’m not sure it is possible to determine
the most immunogenic epitopes on HA,
for example, on the vast variety of flu
strains out there.’’ He adds that flu is
a particularly tough virus to tackle fully.
‘‘We have never been able to eradicate
a pathogen that affects people as long
as there is an animal reservoir,’’ Ross
says. ‘‘For flu, that reservoir is wild birds,
ducks, water fowl.’’
So, until new production practices are
fully vetted, we will still rely on chickens
and fowl to generate both new flu viral
strains and the vaccines that target them.Alice McCarthy (alice@alicemccarthy.com) is
a science writer based in Gloucester, MA.
